

Note: This document has been translated from the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail.

## Summary of Consolidated Financial Results For the First Quarter Ended September 30, 2025 [Japan GAAP]

November 11, 2025

Name of Company: MEDIUS HOLDINGS Co., Ltd.  
 Stock Code: 3154 URL: <https://www.medius.co.jp/>  
 Stock Exchange Listing: Tokyo Stock Exchange, Prime Market  
 Representative Title: President and Representative Director Name: Yasuhiko Ikeya  
 Contact Person Title: Director and General Manager of Corporate Division Name: Hiroyuki Akutagawa  
 Phone: +81-(0)3-6811-2958  
 Date of commencement of dividend payment: -  
 Supplementary explanatory documents: None  
 Earnings presentation: None

(Yen in millions, rounded down)

### 1. Financial results for the first three months ended September 2025 (July 1, 2025 - September 30, 2025)

#### (1) Results of Operations (Consolidated)

(Percentage figures represent year on year changes)

|                               | Net sales   |      | Operating profit |      | Ordinary profit |      | Profit attributable to owners of parent |        |
|-------------------------------|-------------|------|------------------|------|-----------------|------|---|--------|
|                               | Million yen | %    | Million yen      | %    | Million yen     | %    | Million yen                             | %      |
| Three months ended Sept. 2025 | 72,168      | 4.4  | 158              | 3.2  | 269             | 11.1 | 108                                     | 47.1   |
| Three months ended Sept. 2024 | 69,157      | 15.0 | 153              | 70.3 | 242             | 25.8 | 73                                      | (13.5) |

(Note) Comprehensive income: 1Q FY6/26: 30 million yen [(76.6)%] 1Q FY6/25: 128 million yen [- %]

|                               | Earnings per share | Earnings per share fully diluted |
|-------------------------------|--------------------|----------------------------------|
|                               | Yen                | Yen                              |
| Three months ended Sept. 2025 | 4.88               | 4.88                             |
| Three months ended Sept. 2024 | 3.33               | 3.33                             |

#### (2) Financial Position (Consolidated)

|                          | Total assets | Net assets  | Equity ratio |
|--------------------------|--------------|-------------|--------------|
|                          | Million yen  | Million yen | %            |
| As of September 30, 2025 | 117,473      | 20,072      | 17.1         |
| As of June 30, 2025      | 113,024      | 20,478      | 18.1         |

(Reference) Shareholders' equity: As of Sept. 30, 2025: 20,063 million yen  
 As of Jun. 30, 2025: 20,478 million yen

## 2. Dividends

|                       | Dividend per share |           |           |           |       |
|-----------------------|--------------------|-----------|-----------|-----------|-------|
|                       | End of 1Q          | End of 2Q | End of 3Q | End of FY | Total |
|                       | Yen                | Yen       | Yen       | Yen       | Yen   |
| FY6/25                | —                  | 0.00      | —         | 20.00     | 20.00 |
| FY6/26                | —                  |           |           |           |       |
| FY6/26<br>(estimated) |                    | 0.00      | —         | 20.00     | 20.00 |

(Note) Change in the estimation of dividend from the latest announcement: None

## 3. Forecast for the fiscal year ending June 2026 (Consolidated, July 1, 2025 - June 30, 2026)

(Percentage figures represent year on year changes)

|           | Net sales   |     | Operating profit |       | Ordinary profit |       | Profit attributable to owners of parent |       | Earnings per share |
|-----------|-------------|-----|------------------|-------|-----------------|-------|---|-------|--------------------|
|           | Million yen | %   | Million yen      | %     | Million yen     | %     | Million yen                             | %     | Yen                |
| Full year | 305,000     | 5.6 | 1,750            | (6.7) | 2,300           | (5.1) | 1,300                                   | (5.5) | 58.46              |

(Note) Change in the forecast from the latest announcement: None

### \* Notes

(1) Significant changes in the scope of consolidation during the period: Yes

Newly included: 1 company (REPS Corp.)

Excluded: 0 companies ( - )

(Note) For more information, please see “2. Quarterly Consolidated Financial Statements and Important Notes (3) Notes to quarterly consolidated financial statements (Changes in the scope of consolidation or the scope of application of the equity method)” on page 10 of Supplementary Information.

(2) Use of accounting methods specifically for the preparation of the quarterly consolidated financial statements: None

(3) Changes in accounting principles and estimates, and retrospective restatement

(a) Changes in accounting principles due to revision of accounting standards: None

(b) Changes in accounting principles other than in (a): None

(c) Changes in accounting estimates: None

(d) Retrospective restatement: None

(4) Number of shares outstanding (common stock)

|  |                   |            |                |            |
|--|-------------------|------------|----------------|------------|
| (a) Shares outstanding (including treasury shares) | End of 1Q FY6/26: | 22,238,217 | End of FY6/25: | 22,238,217 |
|--|-------------------|------------|----------------|------------|

|                     |                   |     |                |     |
|---------------------|-------------------|-----|----------------|-----|
| (b) Treasury shares | End of 1Q FY6/26: | 958 | End of FY6/25: | 958 |
|---------------------|-------------------|-----|----------------|-----|

|  |            |            |            |            |
|--|------------|------------|------------|------------|
| (c) Average number of shares outstanding | 1Q FY6/26: | 22,237,259 | 1Q FY6/25: | 22,147,522 |
|--|------------|------------|------------|------------|

\* Review of the Japanese-language originals of the attached quarterly consolidated financial statements by certified public accountants or an audit firm: None

\* Cautionary statement regarding forecasts of operating results and special notes

Forward-looking statements in these materials are based on information available to management at the time this report was prepared and assumptions that management believes are reasonable. Actual results may differ significantly from these statements for a number of reasons. For more information about the forecasts, please see “1. Qualitative Information on Quarterly Financial Results (3) An explanation of future predictive data, such as consolidated earnings forecasts” on page 4 of Supplementary Information.

## Index for Supplementary Information

|   |    |
|---|----|
| 1. Qualitative Information on Quarterly Financial Results .....                               | 2  |
| (1) An explanation of operating results .....   | 2  |
| (2) An explanation of financial position .....  | 3  |
| (3) An explanation of future predictive data, such as consolidated earnings forecasts .....   | 4  |
| 2. Quarterly Consolidated Financial Statements and Important Notes .....                      | 5  |
| (1) Quarterly consolidated balance sheet .....  | 5  |
| (2) Quarterly consolidated statements of income and comprehensive income .....                | 7  |
| (Quarterly consolidated statement of income) .....  | 7  |
| (For the three months).....   | 7  |
| (Quarterly consolidated statement of comprehensive income).....                               | 9  |
| (For the three months).....   | 9  |
| (3) Notes to quarterly consolidated financial statements.....                                 | 10 |
| (Notes on going concern assumptions) .....  | 10 |
| (Notes on significant change in shareholders' equity) .....                                   | 10 |
| (Changes in the scope of consolidation or the scope of application of the equity method)..... | 10 |
| (Notes on segment information, etc.).....   | 11 |
| (Notes on quarterly consolidated statements of cash flows) .....                              | 12 |

## 1. Qualitative Information on Quarterly Financial Results

### (1) An explanation of operating results

In the environment surrounding the MEDIUS Group during the first three months of the current fiscal year, in addition to the 2025 problem, a turning point marked by an increase in the elderly population due to advances in medical technology, there are concerns that the medical system will continue to face intermittent strain as a result of salary increases for medical care professionals, the “Work Style Reform for Doctors” implemented since last year, among other factors. Under these circumstances, medical institutions are called on to build a more efficient medical care supply system through the promotion of medical digital transformation (DX), such as online medical consultations and the application of AI in medical care.

Meanwhile, the outlook for the medical sector remains uncertain, as it continues to face challenges such as rising prices and labor costs, the ongoing depreciation of the yen, increasing interest rates, and the introduction of reciprocal tariffs by the United States on various countries.

In this business environment, the MEDIUS Group is conducting business activities based on the policy of ensuring a stable supply of products while resolving customer issues in order to build a sustainable medical system.

During the first three months of the current fiscal year, net sales and gross profit increased compared to the first three months of the previous fiscal year, primarily due to strong sales of replacement supplies used in surgery rooms and other products driven by an increase in sales following an increase in the number of surgical operations and the acquisition of new customers, among other factors.

Selling, general and administrative expenses increased compared to the first three months of the previous fiscal year due to factors such as higher labor costs stemming from personnel hiring and base salary increases associated with business expansion at major subsidiaries, as well as increased outsourcing expenses resulting from higher logistics costs and a rise in provision of allowance for doubtful accounts following the bankruptcy of a business partner. However, operating profit, ordinary profit, and profit attributable to owners of parent increased as a result of higher net sales.

As a result, in the first three months of the current fiscal year, net sales increased 4.4% from a year earlier to 72,168 million yen, operating profit increased 3.2% to 158 million yen, ordinary profit increased 11.1% to 269 million yen, and profit attributable to owners of parent increased 47.1% to 108 million yen.

Business segment performance was as follows.

#### (i) Medical Device

Sales of replacement supplies increased in line with an increase in the number of surgical operations and progress in the acquisition of new customers, mainly in the orthopedic and cardiovascular fields. For medical equipment, although there were sales of large-sized radiotherapy devices during the period, net sales declined compared to the first three months of the previous fiscal year due mainly to the impact of special demand projects in the same period of the previous fiscal year. Nevertheless, net sales for the segment as a whole increased.

In addition, while selling, general and administrative expenses rose due to business expansion and other factors, segment income also increased as a result of higher net sales.

As a result, net sales increased 4.5% from a year earlier to 70,753 million yen, gross profit increased 3.7% to 7,911 million yen, and segment income (operating profit) increased 6.0% to 2,383 million yen.

(ii) Welfare Device

Net sales decreased compared to the first three months of the previous fiscal year, primarily due to the rebound from special demand generated by new facility opening projects during that period. However, gross profit increased, as the new facility opening projects in the previous year had relatively low profit margins, and the high-margin rental business for nursing care equipment performed strongly.

In addition, although selling, general and administrative expenses rose due to an increase in personnel associated with business expansion, the growth in gross profit led to an increase in profit.

As a result, net sales decreased 3.5% from a year earlier to 1,415 million yen, gross profit increased 3.9% to 584 million yen, and segment income (operating profit) increased 11.7% to 116 million yen.

(Note) The business segments of the MEDIUS Group consist of the following activities.

Medical Device

(Medical Device Sales Business)

Sale of medical devices (including equipment and replacement supplies) that are purchased from manufacturers, sales agents, trading companies and other companies in Japan to hospitals and other medical institutions in Japan. This is the core business of the MEDIUS Group.

(Medical Device Repair and Maintenance Business)

Repair and after-sales services for medical devices sold by the MEDIUS Group to hospitals and other medical institutions and maintenance services for all medical devices of a hospital or other medical institution based on a maintenance contract.

Welfare Device

Sale of nursing care and welfare products (including equipment and replacement supplies) that are purchased from manufacturers, sales agents, trading companies and other companies in Japan and other countries to hospitals and other medical institutions, nursing care facilities, medical device sales companies, as well as individuals in Japan. This business also rents nursing care and welfare products to individuals.

(2) An explanation of financial position

A. Assets

Total assets were 117,473 million yen at the end of the first three months of the current fiscal year, 4,448 million yen more than at the end of the previous fiscal year.

Current assets increased 4,553 million yen to 93,606 million yen. This increase was mainly the result of increases of 588 million yen in cash and deposits, 2,392 million yen in notes and accounts receivable – trade, and 1,040 million yen in merchandise and finished goods, and 527 million yen in other current assets, respectively.

Non-current assets decreased 104 million yen to 23,867 million yen. This increase was mainly the result of an increase of 86 million yen in investments and other assets, despite decreases of 69 million yen in property, plant and equipment and 121 million yen in intangible assets, respectively.

B. Liabilities

Total liabilities were 97,401 million yen at the end of the first three months of the current fiscal year, 4,854 million yen more than at the end of the previous fiscal year.

Current liabilities increased 5,137 million yen to 86,517 million yen. This increase was mainly the

result of increases of 4,926 million yen in short-term borrowings and 814 million yen in provision for bonuses, respectively, despite a decrease of 685 million yen in other current liabilities.

Non-current liabilities decreased 283 million yen to 10,883 million yen. This decrease was mainly the result of decreases of 216 million yen in long-term borrowings, 44 million yen in long-term unearned revenue, and 56 million yen in other non-current liabilities, respectively, despite an increase of 24 million yen in retirement benefit liability.

#### C. Net assets

Net assets were 20,072 million yen at the end of the first three months of the current fiscal year, 405 million yen less than at the end of the previous fiscal year. This decrease was mainly the result of decreases of 336 million yen in retained earnings and 79 million yen in valuation difference on available-for-sale securities, respectively.

#### (3) An explanation of future predictive data, such as consolidated earnings forecasts

There is no change to the consolidated earnings forecast for the fiscal year ending June 30, 2026, which was announced on August 7, 2025.

## 2. Quarterly Consolidated Financial Statements and Important Notes

### (1) Quarterly consolidated balance sheet

(Thousand yen)

|  | Fiscal year ended June 2025<br>(As of June 30, 2025) | First quarter ended Sept. 2025<br>(As of Sept. 30, 2025) |
|--|--|--|
| Assets                                 |  |  |
| Current assets                         |  |  |
| Cash and deposits                      | 14,333,767   | 14,922,545   |
| Notes and accounts receivable - trade  | 57,988,850   | 60,381,704   |
| Merchandise and finished goods         | 13,600,867   | 14,641,454   |
| Raw materials and supplies             | 10,963   | 11,195   |
| Other                                  | 3,261,676  | 3,789,460  |
| Allowance for doubtful accounts        | (143,247)  | (140,308)  |
| Total current assets                   | 89,052,879   | 93,606,052   |
| Non-current assets                     |  |  |
| Property, plant and equipment          |  |  |
| Buildings and structures, net          | 7,027,971  | 6,946,830  |
| Machinery, equipment and vehicles, net | 590,856  | 565,830  |
| Land                                   | 3,987,138  | 3,987,138  |
| Other, net                             | 1,494,317  | 1,531,378  |
| Total property, plant and equipment    | 13,100,283   | 13,031,177   |
| Intangible assets                      |  |  |
| Goodwill                               | 1,197,695  | 1,122,850  |
| Other                                  | 1,229,985  | 1,183,268  |
| Total intangible assets                | 2,427,681  | 2,306,119  |
| Investments and other assets           |  |  |
| Other                                  | 8,475,332  | 8,576,558  |
| Allowance for doubtful accounts        | (31,196)   | (46,249)   |
| Total investments and other assets     | 8,444,136  | 8,530,309  |
| Total non-current assets               | 23,972,100   | 23,867,606   |
| Total assets                           | 113,024,980  | 117,473,658  |

(Thousand yen)

|  | Fiscal year ended June 2025<br>(As of June 30, 2025) | First quarter ended Sept. 2025<br>(As of Sept. 30, 2025) |
|--|--|--|
| Liabilities  |  |  |
| Current liabilities  |  |  |
| Notes and accounts payable - trade                                   | 60,110,389   | 60,655,315   |
| Short-term borrowings  | 16,755,998   | 21,682,151   |
| Current portion of bonds payable                                     | 8,000  | 8,000  |
| Income taxes payable   | 682,884  | 375,208  |
| Provision for bonuses  | 62,779   | 876,980  |
| Provision for bonuses for directors (and other officers)             | 168,633  | 14,134   |
| Other  | 3,590,597  | 2,905,468  |
| Total current liabilities  | 81,379,281   | 86,517,257   |
| Non-current liabilities  |  |  |
| Long-term borrowings   | 4,471,997  | 4,255,704  |
| Provision for retirement benefits for directors (and other officers) | 157,000  | 157,000  |
| Provision for share-based payments                                   | 21,837   | 21,880   |
| Provision for loss on guarantees                                     | 106,478  | 115,496  |
| Retirement benefit liability   | 1,543,990  | 1,568,557  |
| Asset retirement obligations   | 162,335  | 162,436  |
| Long-term unearned revenue   | 3,114,030  | 3,069,477  |
| Other  | 1,589,899  | 1,533,428  |
| Total non-current liabilities  | 11,167,568   | 10,883,980   |
| Total liabilities  | 92,546,850   | 97,401,238   |
| Net assets   |  |  |
| Shareholders' equity   |  |  |
| Share capital  | 1,380,877  | 1,380,877  |
| Capital surplus  | 2,879,912  | 2,879,703  |
| Retained earnings  | 14,206,045   | 13,870,035   |
| Treasury shares  | (450)  | (450)  |
| Total shareholders' equity   | 18,466,385   | 18,130,166   |
| Accumulated other comprehensive income                               |  |  |
| Valuation difference on available-for-sale securities                | 1,944,633  | 1,865,204  |
| Remeasurements of defined benefit plans                              | 67,110   | 67,858   |
| Total accumulated other comprehensive income                         | 2,011,744  | 1,933,062  |
| Non-controlling interests  | -  | 9,191  |
| Total net assets   | 20,478,129   | 20,072,420   |
| Total liabilities and net assets                                     | 113,024,980  | 117,473,658  |



(2) Quarterly consolidated statements of income and comprehensive income  
(Quarterly consolidated statement of income)  
(For the three months)

(Thousand yen)

|  | Three months ended Sept. 2024<br>(Jul. 1, 2024 — Sept. 30, 2024) | Three months ended Sept. 2025<br>(Jul. 1, 2025 — Sept. 30, 2025) |
|--|--|--|
| Net sales  | 69,157,000   | 72,168,450   |
| Cost of sales  | 60,975,976   | 63,676,872   |
| Gross profit   | 8,181,024  | 8,491,577  |
| Selling, general and administrative expenses             |  |  |
| Provision of allowance for doubtful accounts             | (15,330)   | 19,204   |
| Provision for share-based payments                       | (6,867)  | 24   |
| Salaries and allowances                                  | 3,317,885  | 3,369,900  |
| Employees' bonuses                                       | 9,720  | 2,022  |
| Provision for bonuses                                    | 794,383  | 817,409  |
| Provision for bonuses for directors (and other officers) | 13,517   | 10,796   |
| Retirement benefit expenses                              | 150,130  | 153,933  |
| Legal welfare expenses                                   | 634,996  | 654,113  |
| Depreciation   | 268,880  | 271,511  |
| Rent expenses  | 600,079  | 625,671  |
| Outsourcing expenses                                     | 631,691  | 674,854  |
| Other  | 1,628,172  | 1,733,483  |
| Total selling, general and administrative expenses       | 8,027,258  | 8,332,926  |
| Operating profit   | 153,765  | 158,651  |
| Non-operating income                                     |  |  |
| Interest income  | 579  | 5,016  |
| Dividend income  | 2,796  | 3,571  |
| Purchase discounts                                       | 82,030   | 83,838   |
| Subsidy income   | 44,552   | 44,552   |
| Other  | 1,980  | 45,594   |
| Total non-operating income                               | 131,939  | 182,573  |
| Non-operating expenses                                   |  |  |
| Interest expenses  | 35,728   | 50,005   |
| Provision for loss on guarantees                         | 857  | 9,018  |
| Other  | 6,621  | 12,806   |
| Total non-operating expenses                             | 43,207   | 71,830   |
| Ordinary profit  | 242,498  | 269,394  |
| Extraordinary income                                     |  |  |
| Gain on sale of non-current assets                       | -  | 1,046  |
| Gain on sale of investment securities                    | -  | 66   |
| Total extraordinary income                               | -  | 1,113  |
| Extraordinary losses                                     |  |  |
| Loss on retirement of non-current assets                 | 823  | 251  |
| Impairment losses  | -  | 3,801  |
| Total extraordinary losses                               | 823  | 4,052  |

(Thousand yen)

|  | Three months ended Sept. 2024<br>(Jul. 1, 2024 — Sept. 30, 2024) | Three months ended Sept. 2025<br>(Jul. 1, 2025 — Sept. 30, 2025) |
|--|--|--|
| Profit before income taxes                     | 241,674  | 266,454  |
| Income taxes - current                         | 374,267  | 368,031  |
| Income taxes - deferred                        | (206,526)  | (210,294)  |
| Total income taxes                             | 167,740  | 157,736  |
| Profit   | 73,933   | 108,717  |
| Loss attributable to non-controlling interests | -  | (18)   |
| Profit attributable to owners of parent        | 73,933   | 108,735  |

(Quarterly consolidated statement of comprehensive income)  
(For the three months)

(Thousand yen)

|  | Three months ended Sept. 2024<br>(Jul. 1, 2024 — Sept. 30, 2024) | Three months ended Sept. 2025<br>(Jul. 1, 2025 — Sept. 30, 2025) |
|--|--|--|
| Profit   | 73,933   | 108,717  |
| Other comprehensive income                                     |  |  |
| Valuation difference on available-for-sale securities          | 53,749   | (79,429)   |
| Remeasurements of defined benefit plans, net of tax            | 621  | 747  |
| Total other comprehensive income                               | 54,371   | (78,682)   |
| Comprehensive income   | 128,305  | 30,035   |
| Comprehensive income attributable to                           |  |  |
| Comprehensive income attributable to owners of parent          | 128,305  | 30,053   |
| Comprehensive income attributable to non-controlling interests | -  | (18)   |

(3) Notes to quarterly consolidated financial statements

(Notes on going concern assumptions)

None

(Notes on significant change in shareholders' equity)

None

(Changes in the scope of consolidation or the scope of application of the equity method)

(Significant changes in the scope of consolidation)

Effective the first quarter of the current fiscal year, REPS Corp., a new company established on July 1, 2025, has been included in the scope of consolidation of KURIBARA MEDICAL Instruments, which is a consolidated subsidiary of the Company.

(Notes on segment information, etc.)

[Segment information]

I First three months of the previous fiscal year (July 1, 2024 — September 30, 2024)

1. Information about sales and income (loss) by reporting segment

(Thousand yen)

|                                 | Reporting segments |                |            | Adjustment<br>(Note 1) | Amount on the<br>consolidated<br>statement of income<br>(Note 2) |
|---------------------------------|--------------------|----------------|------------|------------------------|--|
|                                 | Medical Device     | Welfare Device | Total      |                        |  |
| Net sales                       |                    |                |            |                        |  |
| Sales to outside customers      | 67,690,034         | 1,466,965      | 69,157,000 | —                      | 69,157,000   |
| Intersegment sales or transfers | 7,839              | —              | 7,839      | (7,839)                | —  |
| Total                           | 67,697,873         | 1,466,965      | 69,164,839 | (7,839)                | 69,157,000   |
| Segment income                  | 2,247,239          | 104,130        | 2,351,370  | (2,197,605)            | 153,765  |

(Notes) 1. The 2,197,605 thousand yen negative adjustment for segment income includes 9,954 thousand yen for intersegment transaction eliminations, 74,844 thousand yen deduction for amortization of goodwill and 2,132,714 thousand yen deduction for corporate expenses that cannot be assigned to specific segments. Corporate expenses are primarily operating expenses of parent company and general and administrative expenses that do not belong to specific segments.

2. The segment income matches operating profit in the consolidated statement of income.

II First three months of the current fiscal year (July 1, 2025 — September 30, 2025)

1. Information about sales and income (loss) by reporting segment

(Thousand yen)

|                                 | Reporting segments |                |            | Adjustment<br>(Note 1) | Amount on the<br>consolidated<br>statement of income<br>(Note 2) |
|---------------------------------|--------------------|----------------|------------|------------------------|--|
|                                 | Medical Device     | Welfare Device | Total      |                        |  |
| Net sales                       |                    |                |            |                        |  |
| Sales to outside customers      | 70,753,408         | 1,415,041      | 72,168,450 | —                      | 72,168,450   |
| Intersegment sales or transfers | 4,057              | —              | 4,057      | (4,057)                | —  |
| Total                           | 70,757,466         | 1,415,041      | 72,172,507 | (4,057)                | 72,168,450   |
| Segment income                  | 2,383,156          | 116,354        | 2,499,511  | (2,340,859)            | 158,651  |

(Notes) 1. The 2,340,859 thousand yen negative adjustment for segment income includes 5,019 thousand yen for intersegment transaction eliminations, 74,844 thousand yen deduction for amortization of goodwill and 2,271,034 thousand yen deduction for corporate expenses that cannot be assigned to specific segments. Corporate expenses are primarily operating expenses of parent company and general and administrative expenses that do not belong to specific segments.

2. The segment income matches operating profit in the consolidated statement of income.

2. Information about impairment loss of non-current assets or goodwill by reporting segment

(Important impairment loss of non-current assets)

We are booking impairment loss on non-current assets in the Medical Device segment and the Welfare Device segment. The amount for the first three months of the current fiscal year is 3,645 thousand yen for the Medical Device segment and 156 thousand yen for the Welfare Device segment.

(Notes on quarterly consolidated statements of cash flows)

Consolidated statements of cash flows for the first three months of the current fiscal year have not been prepared. Amounts of depreciation (including amortization of intangible assets other than goodwill) and amortization of goodwill for the first three months of the current fiscal year are as follows:

|                          | Three months ended Sept. 2024<br>(Jul. 1, 2024 — Sept. 30, 2024) | Three months ended Sept. 2025<br>(Jul. 1, 2025 — Sept. 30, 2025) |
|--------------------------|--|--|
| Depreciation             | 408,321 thousand yen   | 452,301 thousand yen   |
| Amortization of goodwill | 74,844 thousand yen  | 74,844 thousand yen  |